Ball & Co Wealth Management’s Summit Therapeutics SMMT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-1,500
Closed -$21K – 65
2026
Q2
$21K Hold
1,500
– – 0.01% 51
2026
Q1
$28K Buy
+1,500
New +$24.3K 0.02% 51
2025
Q4
– Sell
-1,500
Closed -$30K – 84
2025
Q3
$30K Hold
1,500
– – 0.02% 55
2025
Q2
$31K Buy
+1,500
New +$34.2K 0.03% 39

Other funds holding SMMT

Ball & Co Wealth Management's SMMT Position: Q3 2026 in Review

Ball & Co Wealth Management sold out of Summit Therapeutics (SMMT) in Q3 2026, closing a stake of 1,500 shares — an estimated $21K sold.

Ball & Co Wealth Management first reported a position in SMMT in Q2 2025 and held it in 4 quarters. The position peaked at $31K in Q2 2025. 294 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.

  • Ball & Co Wealth Management reported no remaining Summit Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Ball & Co Wealth Management sold 1,500 Summit Therapeutics shares in Q3 2026, an estimated $21K.
  • Ball & Co Wealth Management first reported a position in Summit Therapeutics in Q2 2025 and held it in 4 quarters.
  • Ball & Co Wealth Management's Summit Therapeutics position peaked at $31K in Q2 2025.
  • 294 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.

Based on Ball & Co Wealth Management's 13F filing for Q3 2026, filed 5 Nov 2026.